LEUSTATIN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Feb 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEUSTATIN is a small-molecule injectable indicated for hematologic malignancies, approved in 1993. The drug is a nucleoside analog with immunosuppressive and anti-leukemic activity. Specific mechanism of action and approved indications require clinical context, but the product remains active in oncology.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100) suggests a maturing asset with a consolidating commercial team focused on lifecycle management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LEUSTATIN offers limited career growth opportunities due to its LOE-approaching lifecycle and lack of linked job openings (0 positions). Roles available are primarily focused on risk mitigation, regulatory maintenance, and operational excellence rather than commercial expansion.
Pharmacovigilance SpecialistManufacturing/Supply Chain
Worked on LEUSTATIN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.